Franklin-based Echo Therapeutics has patented its noninvasive wireless glucose monitoring system.
The company’s tCGM, or transdermal continuous glucose monitoring system, has received a patent for use in hospital critical care settings to monitor a patient’s glucose levels over an extended period of time. The patent will expire in 2025.
Echo Therapeutics has applied for similar patents around the world for its noninvasive products, including its SkinPrep system which is a transdermal drug delivery method.
